At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
V565 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment With V565 in Subjects With Active Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating V565 and Placebo for Crohn's Disease. Completed, enrolled 125 participants across 94 sites in 13 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesAustria, Canada, Czechia, Germany, Hungary, Netherlands, Norway, Poland, Serbia, Slovakia, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionMar 2019
TodayJul 2026
First PostedNov 29, 2016
Enrollment StartDec 1, 2016
Primary CompletionMar 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.6 years ago
Interventions
V565drug
Daily dosing of V565 three times a day orally for 6 weeks
Placebodrug
Daily dosing of placebo three times a day orally for 6 weeks